Table Info

Table 1.

Predicted pioneer TFs in ERα dependent BC

Pioneer factors	Molecular/cellular context	Pioneer activity	References
FOXA1	Mitotic biomarker in human hormone-dependent cancer progression	Chromatin decompaction through binding to mitotic chromatin and recruitment of nuclear receptors	[33, 34]
TLE1	Ubiquitous expression in the endometrium, and immunohistochemical biomarker in breast carcinogenesis and synovial sarcoma diagnosis	Multitasking transcriptional corepressor that associate with condensed chromatin by binding to the histone tails of nucleosomes	[44, 45]
PBX1	Specific biomarkers for the diagnosis and prognosis of BC, prostate cancer, and an evident therapeutic target	Translates epigenetic cues and mediates estrogen-induced ERα binding	[28, 46]
AP2γ	The determinant of helix-span-helix domain and its binding affinity to DNA as a dimer is based on the net basic charge, the functional discrepancy of HS-1 hypersensitivity in ER-dependent cancer	Capable of transactivating human ERα promoter in BC through high-affinity AP2 sites in the untranslated leader sequence	[47, 48]
GATA3	Associated with endodermal development	Binds to nucleosomal DNA and actively promote decompaction of chromatin, induce nucleosome eviction	[49]
GATA4	Functionally associated with endodermal development	Capable of binding to compacted chromatin and to open the local nucleosome-rich domains, even in the absence of ATP-dependent chromatin remodeling enzymes, cooperative activity between FOXA1 in chromatin binding	[50, 51]

Declarations

Author contributions

HP and RK conducted conceptualization; HP made draft preparation of the article; RK edited the paper and carried out project administration. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This research was financially supported by Science and Engineering Research Board (SERB) Govt. of India and funded through EMR (2016/003715/BBM) scheme. The research facilities were supported by Central University of Kerala. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Bhagwat AS, Vakoc CR. Targeting transcription factors in cancer. Trends Cancer. 2015;1:53–65. [DOI] [PubMed] [PMC]

Lambert M, Jambon S, Depauw S, David-Cordonnier MH. Targeting transcription factors for cancer treatment. Molecules. 2018;23:1479. [DOI]

Ehsani R, Bahrami S, Drabløs F. Feature-based classification of human transcription factors into hypothetical sub-classes related to regulatory function. BMC Bioinformatics. 2016;17:459. [DOI] [PubMed] [PMC]

Merkulov VM, Merkulova TI. Regulatory transcription factors can control the process of transcription at the stage of pre-mRNA elongation. Russ J Genet Appl Res. 2014;4:549–55. [DOI]

Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381–5. [DOI] [PubMed]

Iwafuchi-Doi M, Zaret KS. Pioneer transcription factors in cell reprogramming. Genes Dev. 2014;28:2679–92. [DOI] [PubMed] [PMC]

Swinstead EE, Paakinaho V, Hager GL. Chromatin reprogramming in breast cancer. Endocr Relat Cancer. 2018;25:R385–404. [DOI] [PubMed] [PMC]

Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011;25:2227–41. [DOI] [PubMed] [PMC]

Siersbæk R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer. Genes Dev. 2018;32:1141–54. [DOI] [PubMed] [PMC]

10.

Morgan D, Garg M, Tergaonkar V, Tan SY, Sethi G. Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2020;1874:188449. [DOI] [PubMed]

11.

Mazo C, Kearns C, Mooney C, Gallagher WM. Clinical decision support systems in breast cancer: a systematic review. Cancers (Basel). 2020;12:369. [DOI]

12.

McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577:89–94. [DOI] [PubMed]

13.

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929–43. [PubMed] [PMC]

14.

Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–24. [DOI] [PubMed] [PMC]

15.

Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G, et al. The dynamic structure of the estrogen receptor. J Amino Acids. 2011;2011:812540. [DOI] [PubMed] [PMC]

16.

Yaşar P, Ayaz G, User SD, Güpür G, Muyan M. Molecular mechanism of estrogen-estrogen receptor signaling. Reprod Med Biol. 2016;16:4–20. [DOI] [PubMed] [PMC]

17.

Palaniappan M, Nguyen L, Grimm SL, Xi Y, Xia Z, Li W, et al. The genomic landscape of estrogen receptor α binding sites in mouse mammary gland. PLoS One. 2019;14:e0220311. [DOI] [PubMed] [PMC]

18.

Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014;14:26–38. [DOI] [PubMed]

19.

Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol. 2008;41:263–75. [DOI] [PubMed] [PMC]

20.

Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6. [DOI] [PubMed] [PMC]

21.

Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251. [DOI] [PubMed] [PMC]

22.

Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115:776–83. [DOI] [PubMed] [PMC]

23.

De Santo I, McCartney A, Migliaccio I, Di Leo A, Malorni L. The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy. Cancers (Basel). 2019;11:1894. [DOI]

24.

Langdon SP. Estrogen receptor signaling in cancer. Cancers (Basel). 2020;12:2744. [DOI]

25.

Lin X, Xiang H, Luo G. Targeting estrogen receptor α for degradation with PROTACs: a promising approach to overcome endocrine resistance. Eur J Med Chem. 2020;206:112689. [DOI] [PubMed]

26.

Oh S, Oh C, Yoo KH. Functional roles of CTCF in breast cancer. BMB Rep. 2017;50:445–53. [DOI] [PubMed] [PMC]

27.

Fiorito E, Sharma Y, Gilfillan S, Wang S, Singh SK, Satheesh SV, et al. CTCF modulates estrogen receptor function through specific chromatin and nuclear matrix interactions. Nucleic Acids Res. 2016;44:10588–602. [DOI] [PubMed] [PMC]

28.

Ross-Innes CS, Brown GD, Carroll JS. A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics. 2011;12:593. [DOI] [PubMed] [PMC]

29.

Paakinaho V, Swinstead EE, Presman DM, Grøntved L, Hager GL. Meta-analysis of chromatin programming by steroid receptors. Cell Rep. 2019;28:3523–34.e2. [DOI] [PubMed] [PMC]

30.

Sekiya T, Muthurajan UM, Luger K, Tulin AV, Zaret KS. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev. 2009;23:804–9. [DOI] [PubMed] [PMC]

31.

Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 2019;571:413–8. [DOI] [PubMed] [PMC]

32.

Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011;30:3885–94. [DOI] [PubMed] [PMC]

33.

Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021;12:29–38. [DOI] [PubMed] [PMC]

34.

Glont SE, Chernukhin I, Carroll JS. Comprehensive genomic analysis reveals that the pioneering function of FOXA1 is independent of hormonal signaling. Cell Rep. 2019;26:2558–65.e3. [DOI] [PubMed] [PMC]

35.

Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222:42–9. [DOI] [PubMed] [PMC]

36.

Emmanuel N, Lofgren KA, Peterson EA, Meier DR, Jung EH, Kenny PA. Mutant GATA3 actively promotes the growth of normal and malignant mammary cells. Anticancer Res. 2018;38:4435–41. [DOI] [PubMed] [PMC]

37.

Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Bennett BD, Myers P, et al. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun. 2018;9:1059. [DOI] [PubMed] [PMC]

38.

Hruschka N, Kalisz M, Subijana M, Graña-Castro O, Del Cano-Ochoa F, Brunet LP, et al. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene. 2020;39:5455–67. [DOI] [PubMed] [PMC]

39.

Chaudhary S, Krishna BM, Mishra SK. A novel FOXA1/ESR1 interacting pathway: a study of Oncomine™ breast cancer microarrays. Oncol Lett. 2017;14:1247–64. [DOI] [PubMed] [PMC]

40.

Kong SL, Li G, Loh SL, Sung WK, Liu ET. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol. 2011;7:526. [DOI] [PubMed] [PMC]

41.

Holmes KA, Hurtado A, Brown GD, Launchbury R, Ross-Innes CS, Hadfield J, et al. Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci U S A. 2012;109:2748–53. [DOI] [PubMed] [PMC]

42.

Ao X, Ding W, Ge H, Zhang Y, Ding D, Liu Y. PBX1 is a valuable prognostic biomarker for patients with breast cancer. Exp Ther Med. 2020;20:385–94. [DOI] [PubMed] [PMC]

43.

Manavathi B, Samanthapudi VS, Gajulapalli VN. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front Cell Dev Biol. 2014;2:34. [DOI] [PubMed] [PMC]

44.

Fiorito E, Katika MR, Hurtado A. Cooperating transcription factors mediate the function of estrogen receptor. Chromosoma. 2013;122:1–12. [DOI] [PubMed] [PMC]

45.

Yuan D, Yang X, Yuan Z, Zhao Y, Guo J. TLE1 function and therapeutic potential in cancer. Oncotarget. 2017;8:15971–6. [DOI] [PubMed] [PMC]

46.

Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, et al. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget. 2015;6:21878–91. [DOI] [PubMed] [PMC]

47.

Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 2018;7:24. [DOI] [PubMed] [PMC]

48.

Pinzone JJ, Stevenson H, Strobl JS, Berg PE. Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol. 2004;24:4605–12. [DOI] [PubMed] [PMC]

49.

Jiang G, Wang X, Sheng D, Zhou L, Liu Y, Xu C, et al. Cooperativity of co-factor NR2F2 with pioneer factors GATA3, FOXA1 in promoting ERα function. Theranostics. 2019;9:6501–16. [DOI] [PubMed] [PMC]

50.

Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002;9:279–89. [DOI] [PubMed]

51.

Mayran A, Drouin J. Pioneer transcription factors shape the epigenetic landscape. J Biol Chem. 2018;293:13795–804. [DOI] [PubMed] [PMC]

52.

Robinson JL, Holmes KA, Carroll JS. FOXA1 mutations in hormone-dependent cancers. Front Oncol. 2013;3:20. [DOI] [PubMed] [PMC]

53.

Gan HY, Li N, Zhang Q, Feng ZZ. Silencing FOXA1 gene regulates liver cancer cell apoptosis and cell proliferation. Eur Rev Med Pharmacol Sci. 2018;22:397–404. [DOI] [PubMed]

54.

Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, et al. Mutation of GATA3 in human breast tumors. Oncogene. 2004;23:7669–78. [DOI] [PubMed]

55.

Kirtonia A, Pandya G, Sethi G, Pandey AK, Das BC, Garg M. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. J Mol Med (Berl). 2020;98:1069–91. [DOI] [PubMed]

56.

Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126:2491–501. [DOI] [PubMed] [PMC]

57.

Kansara S, Pandey V, Lobie PE, Sethi G, Garg M, Pandey AK. Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer. Cells. 2020;9:1511. [DOI]

58.

Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinković D, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014;5:5165. [DOI] [PubMed] [PMC]

59.

Zhao J, Hu C, Wang C, Yu W, Guo Y, Shi M, et al. Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases. BMC Cancer. 2018;18:1290. [DOI] [PubMed] [PMC]

60.

Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu J, et al. FoxM1: a novel tumor biomarker of lung cancer. Int J Clin Exp Med. 2015;8:3136–40. [PubMed] [PMC]

61.

Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173:489–97. [DOI] [PubMed] [PMC]

62.

Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215:895–910. [DOI] [PubMed] [PMC]

63.

Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 1994;264:1455–8. [DOI] [PubMed]

64.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, et al. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Mol Oncol. 2018;12:1884–94. [DOI] [PubMed] [PMC]

65.

Carroll JS. Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 2016;175:R41–9. [DOI] [PubMed] [PMC]

66.

Yamaguchi N, Nakayama Y, Yamaguchi N. Down-regulation of forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 2017;292:8136–48. [DOI] [PubMed] [PMC]

67.

Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, et al. FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer. Cancer Cell. 2020;38:534–50.e9. [DOI] [PubMed]

68.

Lin HY, Zeng D, Liang YK, Wei XL, Chen CF. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies. Oncotarget. 2017;8:34750–61. [DOI] [PubMed] [PMC]

69.

Wang J, Shidfar A, Ivancic D, Ranjan M, Liu L, Choi MR, et al. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. Int J Cancer. 2017;140:2484–97. [DOI] [PubMed]

70.

Lee JH, Bae SB, Oh MH, Cho HD, Jang SH, Hong SA, et al. Clinicopathologic and prognostic significance of transducin-like enhancer of split 1 protein expression in invasive breast cancer. J Breast Cancer. 2017;20:45–53. [DOI] [PubMed] [PMC]